AKEBIA THERAPEUTICS, INC. (AKBA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $1.73B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $1.72B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $1.72B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $1.71B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.00K.
AKEBIA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital USD | Treasury Stock, Value USD | Treasury Stock, Value, Acquired, Cost Method USD | Treasury Stock, Retired, Cost Method, Amount USD | Treasury Stock, Shares, Retired shares | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD | Adjustments to Additional Paid in Capital, Other USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $2.00K | $1.73B | $6.00K | $-1.70B | $25.02M | 3 month · $3.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $2.00K | $1.72B | $6.00K | $-1.69B | $27.38M | 3 month · $3.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $2.00K | $1.72B | $6.00K | $-1.68B | $32.61M | 12 month · $11.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $2.00K | $1.71B | $6.00K | $-1.67B | $41.59M | 3 month · $3.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $2.00K | $1.70B | $6.00K | $-1.67B | $29.22M | 3 month · $2.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $2.00K | $1.70B | $6.00K | $-1.67B | $24.58M | 3 month · $2.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $2.00K | $1.63B | $6.00K | $-1.68B | $-49.19M | 12 month · $7.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $2.00K | $1.61B | $6.00K | $-1.66B | $-50.40M | 3 month · $1.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $2.00K | $1.60B | $6.00K | $-1.64B | $-33.75M | 3 month · $2.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $2.00K | $1.60B | $6.00K | $-1.63B | $-27.26M | 3 month · $2.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $2.00K | $1.58B | $6.00K | $-1.61B | $-30.58M | 12 month · $9.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $2.00K | $1.57B | $6.00K | $-1.61B | $-39.42M | 3 month · $1.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $2.00K | $1.57B | $6.00K | $-1.60B | $-26.80M | 3 month · $3.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $2.00K | $1.56B | $6.00K | $-1.58B | $-19.12M | 3 month · $2.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $2.00K | $1.56B | $6.00K | $-1.56B | $5.23M | 12 month · $17.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $2.00K | $1.56B | $6.00K | $-1.55B | $8.26M | 3 month · $3.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $2.00K | $1.56B | $6.00K | $-1.50B | $58.94M | 3 month · $6.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $2.00K | $1.55B | $6.00K | $-1.53B | $22.58M | 3 month · $4.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $1.00K | $1.54B | $6.00K | $-1.46B | $74.01M | 12 month · $22.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $0.00 | $2.00K | $1.53B | $6.00K | $-1.39B | $137.15M | 3 month · $5.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $2.00K | $1.50B | $6.00K | $-1.33B | $174.63M | 3 month · $6.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $0.00 | $2.00K | $1.46B | $9.00K | $-1.25B | $213.89M | 3 month · $5.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $1.00K | $1.43B | $13.00K | $-1.18B | $244.35M | 12 month · $24.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $0.00 | $1.00K | $1.41B | $6.00K | $-1.09B | $317.96M | 3 month · $6.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $1.00K | $1.40B | $-9.00K | $-1.03B | $370.26M | 3 month · $6.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.00K | $1.25B | (m) | $-854.80M | $396.36M | 3 month · $4.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $1.00K | $1.19B | $0.00 | $-794.05M | $392.88M | 12 month · $11.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.00K | $1.17B | $6.00K | $-699.57M | $467.56M | 3 month · $2.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.00K | $1.16B | $23.00K | $-644.99M | $519.36M | 3 month · $2.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.00K | $1.15B | $-36.00K | $-586.82M | $566.38M | 3 month · $2.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.00K | $1.15B | $-261.00K | $-514.39M | $635.93M | 3 month · $12.06M 12 month · $19.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.00K | $597.29M | $-409.00K | $-454.34M | $142.54M | 3 month · $2.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.00K | $594.68M | $-459.00K | $-428.29M | $165.92M | 3 month · $2.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.00K | $591.87M | $-550.00K | $-394.23M | $197.10M | 3 month · $2.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $0.00 | $493.82M | $-442.00K | $-370.81M | $122.57M | 12 month · $8.87M | (m) | (m) | (m) | (m) | (m) | 12 month · $3.41M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $0.00 | $486.39M | $-181.00K | $-386.33M | $99.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $0.00 | $420.45M | $-254.00K | $-363.20M | $57.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $0.00 | $372.48M | $-179.00K | $-341.68M | $30.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $0.00 | $365.30M | $-42.00K | $-297.14M | $68.12M | 12 month · $5.83M | (m) | (m) | (m) | (m) | 12 month · 8.64K | (m) | (m) | (m) | 0.00 |
| 2016-09-30 | (m) | $0.00 | $359.99M | $-7.00K | $-259.27M | $100.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2016-06-30 | (m) | $0.00 | $356.22M | $37.00K | $-222.97M | $133.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2016-03-31 | (m) | $0.00 | $355.14M | $-27.00K | $-187.19M | $167.76M | (m) | (m) | $162.00K | (m) | (m) | (m) | (m) | (m) | (m) | 8.46K |
| 2015-12-31 | (m) | $0.00 | $292.78M | $-234.00K | $-161.39M | $131.00M | 12 month · $4.71M | (m) | $162.00K | (m) | (m) | (m) | (m) | (m) | (m) | 8.64K |
| 2015-09-30 | (m) | $0.00 | $287.11M | $-7.00K | $-141.53M | $145.41M | (m) | (m) | $162.00K | (m) | (m) | (m) | (m) | (m) | (m) | 8.46K |
| 2015-06-30 | (m) | $0.00 | $272.00M | $-27.00K | $-122.06M | $149.75M | (m) | (m) | $162.00K | (m) | (m) | (m) | (m) | (m) | (m) | 8.46K |
| 2015-03-31 | (m) | $0.00 | $206.15M | $-8.00K | $-111.37M | $94.61M | (m) | (m) | $161.00K | (m) | (m) | (m) | (m) | (m) | (m) | 8.46K |
| 2014-12-31 | (m) | $0.00 | $204.97M | $-56.00K | $-100.67M | $104.08M | 12 month · $6.01M | (m) | $162.00K | 12 month · $94.00K | 12 month · $68.00K | (m) | (m) | (m) | 12 month · $237.00K | 8.46K |
| 2014-09-30 | (m) | (m) | (m) | $-51.26K | $-90.30M | $113.61M | (m) | $204.05M | $79.00K | (m) | (m) | (m) | (m) | (m) | (m) | 2.55K |
| 2014-06-30 | (m) | $202.00 | (m) | $-8.22K | $-80.95M | $121.55M | (m) | $202.54M | $21.36K | (m) | (m) | (m) | (m) | 6 month · $86.90M | (m) | 775.00 |
| 2014-03-31 | (m) | $202.00 | (m) | (m) | (m) | $127.87M | (m) | $201.20M | (m) | (m) | (m) | (m) | (m) | 3 month · $86.90M 85 month · $153.64M | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | $0.00 | $-127.07M | $-127.07M | 12 month · $1.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 2.55K |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $49.27M 6 month · $50.11M | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $848.12K | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | $-59.59M | 12 month · $122.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | $-48.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |